Abdul-Hamed, S., Ashry, M., Mousa, N., Saleh, A., Abdel-Ghani, A. (2022). Studying Sclerostin in Hemodialysis and after Kidney Transplantation in Egyptian Populations and Its Relation to Vascular Calcification: A Single Center Study. The Egyptian Journal of Hospital Medicine, 89(2), 6348-6355. doi: 10.21608/ejhm.2022.269784
Samir Kamal Abdul-Hamed; Mahmoud Ali Mahmoud Ashry; Nabeela Faiq Amin Mousa; Ahmed Faisal Mohamed Mohamed Saleh; Amal Abdel-Aziz Mahmoud Abdel-Ghani. "Studying Sclerostin in Hemodialysis and after Kidney Transplantation in Egyptian Populations and Its Relation to Vascular Calcification: A Single Center Study". The Egyptian Journal of Hospital Medicine, 89, 2, 2022, 6348-6355. doi: 10.21608/ejhm.2022.269784
Abdul-Hamed, S., Ashry, M., Mousa, N., Saleh, A., Abdel-Ghani, A. (2022). 'Studying Sclerostin in Hemodialysis and after Kidney Transplantation in Egyptian Populations and Its Relation to Vascular Calcification: A Single Center Study', The Egyptian Journal of Hospital Medicine, 89(2), pp. 6348-6355. doi: 10.21608/ejhm.2022.269784
Abdul-Hamed, S., Ashry, M., Mousa, N., Saleh, A., Abdel-Ghani, A. Studying Sclerostin in Hemodialysis and after Kidney Transplantation in Egyptian Populations and Its Relation to Vascular Calcification: A Single Center Study. The Egyptian Journal of Hospital Medicine, 2022; 89(2): 6348-6355. doi: 10.21608/ejhm.2022.269784
Studying Sclerostin in Hemodialysis and after Kidney Transplantation in Egyptian Populations and Its Relation to Vascular Calcification: A Single Center Study
Background: Vascular calcification has been shown as a critical indicator of cardiovascular diseases and all-cause mortality in patients with chronic kidney disease. Patients with chronic kidney disease and vascular calcification were suggested to be considered at the highest cardiovascular disease risk by the kidney disease. The current study aimed to assess level of sclerostin in patients on haemodialysis and its association with vascular calcification. Patients and methods: The current study included 29 patients received a renal transplant at least 12 months ago (transplant group), 34 patients who diagnosed wth (end stage kidney disease) ESKD and receiving regular haemodialysis (ESKD group) and 30 normal individuals (control group). All cases were subjected to laboratory data including sclerostin level assessment. In addition, echocardiography and carotid intima media thickness was assessed by Duplex in patient’s group. Results: The study found that majority of subjects was males. Also, frequency of diabetes mellitus was significantly higher among dialysis group. Dialysis group had significtly higher level of sclerostin in comparison to other groups. Vascular calcification was present in 31% of transplant group and 38.2% of dialysis group. Dialysis and transplant groups had significantly higher intima media thickness but with significantly lower bone mineral density in comparison to the control group. Sclerostin had negative significant correlation with glomerular filtration rate and serum calcium and positive significant correlation with serum phosphate, parathermone hormone and intima media thickness. Conclusion: Patients with chronic kidney disease are vulnerable to develop vascular calcification. This complication is usually increasing the cardiovascular morbidity in those patients. Multi center future studies are warranted to confirm the role of sclerostin.